| Literature DB >> 31801899 |
Erin P Balogh1, Andrew B Bindman2, S Gail Eckhardt3, Susan Halabi4, R Donald Harvey5, Ishmael Jaiyesimi6, Rebecca Miksad7, Harold L Moses8, Sharyl J Nass9, Richard L Schilsky10, Steven Sun11, Josephine M Torrente12, Katherine E Warren13.
Abstract
A number of important drugs used to treat cancer-many of which serve as the backbone of modern chemotherapy regimens-have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice.Keywords: Cancer; Drug approval; Drug legislation; Drug prescriptions; Pharmaceutical research
Year: 2019 PMID: 31801899 DOI: 10.1634/theoncologist.2019-0698
Source DB: PubMed Journal: Oncologist ISSN: 1083-7159